Effect of Some Drugs on Liver Fibrosis

December 7, 2018 updated by: Sherief Abd-Elsalam

Clinical Study Evaluating the Efficacy of Renin Angiotensin System Inhibitors on the Extent of Liver Fibrosis in Patients With Chronic Hepatitis C

Effect of Some Drugs on Liver Fibrosis

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

The study aimed at evaluating the effect of Some Drugs on Liver Fibrosis

Study Type

Interventional

Enrollment (Anticipated)

45

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
      • Tanta, Egypt, 35111
        • Recruiting
        • Sherief Abd-Elsalam
        • Contact:
          • Abeer Abd-Almohsen, Msc

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • chronic hepatitis C

Exclusion Criteria:

  • Acute hepatitis
  • Thalassemia

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Control group
No intervention
Active Comparator: Candesartan
Candesartan 8 mg/day
Drug: Candesartan
Candesartan 8 mg/day
Other Names:
  • Cansartan
Active Comparator: Ramipril
Ramipril 1.25 mg/day
Drug: Ramipril
ramipril 1.25 mg/day

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Fibroscan or APRI score
Time Frame: 6 months
Change in Fibroscan or APRI score
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sherief Abd-Elsalam

Investigators

  • Principal Investigator: Gamal El-azab, Prof, Clinical pharmacy Department- Tanta University
  • Study Director: Tarek Mostafa, Prof, Cardiology Department- Tanta University
  • Study Chair: Gamal Badra, Prof, National Hepatology Institute - Egypt
  • Study Chair: Abeer El-Motwally, Msc, Clinical pharmacy Department-Tanta University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 1, 2018

Primary Completion (Anticipated)

October 1, 2026

Study Completion (Anticipated)

November 1, 2027

Study Registration Dates

First Submitted

December 7, 2018

First Submitted That Met QC Criteria

December 7, 2018

First Posted (Actual)

December 10, 2018

Study Record Updates

Last Update Posted (Actual)

December 10, 2018

Last Update Submitted That Met QC Criteria

December 7, 2018

Last Verified

December 1, 2018

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • liver fibrosis

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Liver Fibroses

Clinical Trials on Candesartan

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Chile

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe